Galapagos shifts to CAR-T therapy with GLPG5101, targeting pivotal trials by 2026. Click here to find out why I rate GLPG ...

Galapagos NV’s split could unlock value despite short-term share decline. Learn why GLPG stock’s strategic focus offers ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Galapagos NV ( AMS:GLPG ) shareholders should be happy to see the share price up 13% in the last week. But will ...

Fintel reports that on February 14, 2025, Morgan Stanley downgraded their outlook for Galapagos NV - Depositary Receipt () ...

In a report released on February 13, Brian Abrahams from RBC Capital maintained a Hold rating on Galapagos (GLPG – Research Report), with a ...

Deutsche Bank lowered the firm’s price target on Galapagos (GLPG) to EUR 22 from EUR 28 and keeps a Hold rating on the shares.Discover the Best ...

Galapagos NV (NASDAQ:GLPG) received FDA's IND clearance to begin clinical studies in the US for their CD19 CAR-T program, GLPG5101. The company reported strong clinical data from the ATLANTA study ...

Galapagos NV (GLPG) reports strong financials and strategic advancements amid increased R&D expenses and operational ...

In this article, we are going to take a look at where Galapagos NV (NASDAQ:GLPG) stands against the other cheap biotech stocks. Biotechnology stocks are among the most volatile in the market due ...